


In the claims, please enter the amendments to the claims submitted in the Response to the Office Action mailed on July 27, 2006. Further, please cancel claims 31, and 58-69 as set forth below in the listing of claims. The listing of claims will replace all prior versions and listings of the claims in the application.

Listing of Claims:

1-26 (Previously cancelled)

27 (Previously Amended) A pharmaceutical composition comprising, in association with a pharmaceutically acceptable diluent or carrier, a compound of the formula



or a salt, metal complex or hydrate or other solvate thereof, wherein:

M is BX₂, wherein each X is independently a halide;

each R¹, R³, R⁴ and R⁶ is independently selected from the group consisting of: H; a substituted or unsubstituted, saturated or unsaturated, cyclic, moiety; a substituted or unsubstituted, saturated or unsaturated, heterocyclic moiety; or a substituted or unsubstituted, saturated or unsaturated, straight or branched chain alkyl or acyl moiety; and

each R² and R⁵ is independently selected from a heavy atom or an alkyl, cyclic, or heterocyclic moiety each substituted with at least one heavy atom.

28 (Previously Cancelled)

29 (Previously Cancelled)

30 (Previously Cancelled)

31 (Cancelled)

32 (Previously Cancelled)

33 (Previously Cancelled)

34 (Previously Cancelled)

35 (Previously Cancelled)

36 (Previously Cancelled)

37. (Previously Presented) The pharmaceutical composition of claim 27, wherein R^2 and R^5 are each independently selected from At, I, Br, and Cl.

38. (Previously Presented) The pharmaceutical composition of claim 27, wherein R^1 and R^6 are each independently substituted or unsubstituted, unsaturated, monocyclic or polycyclic aromatic hydrocarbon moiety.

39. (Previously Presented) The pharmaceutical composition of claim 38, wherein R^1 and R^6 are each independently substituted or unsubstituted phenyl.


40. (Previously Presented) The pharmaceutical composition of claim 39, wherein R^1 and R^6 are each independently phenyl substituted with an electron-donating substituent.

41. (Previously Presented) The pharmaceutical composition of claim 40, wherein the electron-donating substituent is an alkoxy or a substituted or unsubstituted, saturated or unsaturated, straight or branched chain alkyl moiety.

42. (Previously Presented) The pharmaceutical composition of claim 41, wherein the electron-donating substituent is an alkoxy.

43. (Previously Presented) The pharmaceutical composition of claim 27, wherein R^3 and R^4 are each independently substituted or unsubstituted phenyl.

44. (Previously Presented) The pharmaceutical composition of claim 43, wherein R^3 and R^4 are each independently phenyl substituted with one or more heavy atoms.
45. (Previously Presented) The pharmaceutical composition of claim 44, wherein each heavy atom is At, I, Br, or Cl.
46. (Previously Presented) The pharmaceutical composition of claim 43, wherein R^3 and R^4 are each independently phenyl substituted with a carboxylic acid, sulfonic acid, phenol, alcohol, amine, amide, tetrazole, sulphonamide or ester.
47. (Previously Presented) A compound of the formula:



or a salt, metal complex or hydrate or other solvate thereof, wherein:

M is BX_2 , wherein each X is independently a halide;

each R^1 , R^3 , R^4 , and R^6 is independently selected from the group consisting of H, substituted or unsubstituted, saturated or unsaturated, cyclic, moiety; substituted or unsubstituted, saturated or unsaturated, heterocyclic moiety; and substituted or unsubstituted, saturated or unsaturated, straight or branched chain alkyl or acyl moiety; and

each R^2 and R^5 is independently selected from a heavy atom or an alkyl, cyclic, or heterocyclic moiety each substituted with at least one heavy atom.

48. (Previously Presented) The compound of claim 47, wherein R^2 and R^5 are each independently selected from At, I, Br, and Cl.

49. (Previously Presented) The compound of claim 47, wherein R^1 and R^6 are each independently substituted or unsubstituted, unsaturated, monocyclic or polycyclic aromatic hydrocarbon moiety.
50. (Previously Presented) The compound of claim 49, wherein R^1 and R^6 are each independently substituted or unsubstituted phenyl.
51. (Previously Presented) The compound of claim 50, wherein R^1 and R^6 are each independently phenyl substituted with an electron-donating substituent.
52. (Previously Presented) The compound of claim 51, wherein the electron-donating substituent is an alkoxy or a substituted or unsubstituted, saturated or unsaturated, straight or branched chain alkyl moiety.
53. (Previously Presented) The compound of claim 52, wherein the electron-donating substituent is an alkoxy.
54. (Previously Presented) The compound of claim 47, wherein R^3 and R^4 are each independently substituted or unsubstituted phenyl.
55. (Previously Presented) The compound of claim 54, wherein R^3 and R^4 are each independently phenyl substituted with one or more heavy atoms.
56. (Previously Presented) The compound of claim 55, wherein each heavy atom is At, I, Br, or Cl.
57. (Previously Presented) The compound of claim 54, wherein R^3 and R^4 are each independently phenyl substituted with a carboxylic acid, sulfonic acid, phenol, alcohol, amine, amide, tetrazole, sulphonamide, or ester.
58. (Cancelled)

59. (Cancelled)

60. (Cancelled)

61. (Cancelled)

62. (Cancelled)

63. (Cancelled)

64. (Cancelled)

65. (Cancelled)

66. (Cancelled)

67. (Cancelled)

68. (Cancelled)

69. (Cancelled)